Using machine learning to explore unknown chemicals in the body
A machine-learning platform to illuminate the chemical dark matter in mass spectrometry-based metabolomics
['FUNDING_OTHER'] · PRINCETON UNIVERSITY · NIH-10910517
This study is working on new computer tools to help scientists understand tiny molecules in our bodies that could affect our health, with the hope that this knowledge will lead to more personalized treatments for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PRINCETON UNIVERSITY (nih funded) |
| Locations | 1 site (Princeton, UNITED STATES) |
| Trial ID | NIH-10910517 on ClinicalTrials.gov |
What this research studies
This research focuses on developing advanced computational tools to analyze mass spectrometry data, which captures thousands of small molecules in the human body. By illuminating the so-called 'chemical dark matter,' the project aims to identify previously unknown metabolites that could play a role in health and disease. The approach combines cutting-edge machine learning techniques with metabolomics to enhance our understanding of how these chemicals affect human biology. Patients may benefit from insights gained through this research, which could lead to more personalized medical treatments based on individual metabolic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with metabolic disorders or those interested in how their unique chemical makeup affects their health.
Not a fit: Patients with well-defined metabolic profiles that are already fully understood may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to breakthroughs in understanding diseases and developing personalized medicine strategies.
How similar studies have performed: Other research has shown promise in using computational tools to analyze complex biological data, suggesting that this approach could yield valuable insights.
Where this research is happening
Princeton, UNITED STATES
- PRINCETON UNIVERSITY — Princeton, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SKINNIDER, MICHAEL ALEXANDER — PRINCETON UNIVERSITY
- Study coordinator: SKINNIDER, MICHAEL ALEXANDER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.